← Writing/Microbiome Research

The Overlooked Role of Zinc Dyshomeostasis in Multiple Sclerosis Pathogenesis

·6 min read
The Overlooked Role of Zinc Dyshomeostasis in Multiple Sclerosis Pathogenesis

Multiple Sclerosis (MS) is a complex autoimmune disorder characterized by demyelination and neurodegeneration in the central nervous system. While genetic, environmental, and immunological factors have long been implicated in its etiology, emerging research highlights the potential role of trace elements like zinc in disease pathogenesis. Zinc, an essential metal abundant in the brain, plays a critical role in neuronal function, immune regulation, and cellular homeostasis. However, disruptions in zinc balance—known as dyshomeostasis—may contribute to neurological disorders, including MS

In this blog post, I explore the evidence linking zinc dysregulation to MS, drawing on recent meta-analyses, animal models, historical observations, and microbiome studies. I'll also address why current interventions often overlook zinc homeostasis and discuss the nuances of zinc supplementation in MS management. This discussion is informed by scientific literature, with citations provided for further reading.

Zinc in Brain Health and MS: Key Findings from Recent Research

Zinc is predominantly stored in presynaptic vesicles of neurons, where it modulates synaptic transmission and neuroprotection. Excessive zinc can be neurotoxic, while deficiency leads to neuronal cell death, underscoring the need for precise homeostasis (Choi et al., 2018). A 2016 systematic review and meta-analysis examined zinc levels in MS patients, revealing reduced serum or plasma zinc compared to healthy controls, but elevated levels in whole blood and erythrocytes (Bredholt & Frederiksen, 2016). These discrepancies suggest localized zinc alterations may drive MS pathogenesis, rather than systemic deficiency alone.

This hypothesis aligns with the idea that zinc imbalances could exacerbate inflammation and demyelination, hallmarks of MS.

Critiquing the Delayed Recognition of Zinc's Role

Despite these findings, the scientific community has been slow to prioritize zinc in MS research. Here are three compelling reasons why this oversight is noteworthy:

  • Animal Models of MS Induction: The cuprizone model, widely used to study MS, involves administering cuprizone—a copper chelator—that disrupts the zinc/copper ratio, leading to elevated zinc levels, oligodendrocyte damage, and widespread demyelination (Praet et al., 2014). This model directly implicates zinc excess in myelin breakdown, yet its implications for human MS are under-explored.**

  • Elevated Calprotectin in MS**: Calprotectin, a protein that sequesters zinc to limit its availability to pathogens (a process known as nutritional immunity), is significantly elevated in MS patients (Ristori et al., 2023). This elevation may reflect an immune response to zinc dysregulation, further linking zinc to disease progression.**

  • Historical Occupational Exposures**: Since the 1950s, case studies have reported disproportionately high MS rates in certain professions exposed to zinc. For instance, zinc miners and workers in zinc-related manufacturing plants showed elevated incidence (Hopkins et al., 1987). Similarly, leather and rubber workers, often exposed to zinc-based solvents, and school teachers following the introduction of zinc oxide in dustless chalk, exhibited increased risk (Landtblom et al., 1996). These observations suggest chronic zinc exposure as a potential environmental trigger.

In summary, evidence from animal models, biomarkers like calprotectin, and occupational epidemiology points to zinc's involvement in MS—yet comprehensive hypotheses are only now emerging.

Additional Contextual Factors

Several other lines of evidence bolster this connection:

  • Geographical Patterns: MS prevalence is higher in forested areas with copper-deficient soils, potentially disrupting zinc/copper balance (Stein et al., 2016). This environmental factor remains puzzling but may relate to altered trace metal availability.**

  • Microbiome and Pathogen Associations**: Certain pathogens thrive in zinc-rich environments and are linked to MS progression. Staphylococcus aureus, Akkermansia muciniphila, Bifidobacteria, Pseudomonas aeruginosa, and Proteus mirabilis are overrepresented in MS microbiomes (Mirza et al., 2022). These bacteria utilize zinc for virulence, producing zinc metalloproteases to acquire iron and evade immunity (Cassat & Skaar, 2015, DOI: 10.1039/c5mt00170f). Notably, vancomycin—a zinc-chelating antibiotic—has shown experimental promise in MS treatment by modulating gut microbiota (Chen et al., 2023).**

  • Chelation Therapies**: Clioquinol, a zinc chelator, has reversed MS-like symptoms in animal models until excessive use disrupts zinc/copper ratios (Choi et al., 2013). Fecal microbiota transplants (FMT) from MS patients induce experimental autoimmune encephalomyelitis (EAE) in mice, highlighting microbiome-zinc interactions (Cekanaviciute et al., 2017).**

  • Disease Progression and Related Conditions**: As MS advances, zinc depletes due to consumption by the body and pathogens. Myelin itself is zinc-rich, making it vulnerable to dyshomeostasis (Miyamoto et al., 2010). Amyotrophic Lateral Sclerosis (ALS), another neurodegenerative condition, shares zinc-mediated mechanisms and microbiome signatures with MS (Boddy et al., 2021).

Two Key Questions for MS Research and Treatment

Considering this evidence, two questions arise:

  • Why Don't MS Interventions Prioritize Zinc Homeostasis? Given that manipulating zinc levels induces MS in animal models, it's surprising that most strategies focus on immunomodulation rather than trace metal balance. This gap represents a potential avenue for novel therapies.**

  • Is Zinc Supplementation Appropriate for MS Patients?** Physicians often recommend supplementation due to low serum zinc, but this may be misguided. Elevated calprotectin, vancomycin's efficacy, and clioquinol studies suggest chelation could be beneficial. Pathogens in MS microbiomes express ZnuA, a high-affinity zinc uptake protein, allowing them to assimilate supplemental zinc for virulence (Pederick et al., 2015). Thus, adding zinc might fuel pathogens rather than aid the host.

One exception is zinc aspartate, which appears less assimilable by pathogens while bioavailable to human cells (Kahraman et al., 2017). This form warrants further investigation for MS patients.

Initially high serum zinc in early MS may decline due to pathogen-driven upregulation of zinc-dependent matrix metalloproteinases (MMPs), which degrade myelin (Pawlitzki et al., 2018).

Conclusion

Zinc dyshomeostasis offers a unifying framework for understanding MS pathogenesis, integrating environmental, microbial, and biochemical factors. By addressing this overlooked element, we may unlock more effective interventions. As always, consult healthcare professionals before altering supplements or treatments. I'd love to hear your thoughts in the comments—let's continue the conversation.

References

  • Bredholt, M., & Frederiksen, J. L. (2016). Zinc in Multiple Sclerosis: A Systematic Review and Meta-Analysis. ASN Neuro, 8(3). https://doi.org/10.1177/1759091416651511

  • Cassat, J. E., & Skaar, E. P. (2015). Iron and zinc exploitation during bacterial pathogenesis. Metallomics, 7(11), 1431-1443. https://doi.org/10.1039/c5mt00170f

  • Cekanaviciute, E., et al. (2017). Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proceedings of the National Academy of Sciences, 114(40), 10713-10718. https://doi.org/10.1073/pnas.1711235114

  • Chen, H., et al. (2023). Oral vancomycin treatment suppresses gut trypsin activity and preserves intestinal barrier function during EAE in mice. JCI Insight, 8(19). https://doi.org/10.1172/jci.insight.170816

  • Choi, B. Y., et al. (2013). Copper/zinc chelation by clioquinol reduces spinal cord white matter damage and behavioral deficits in a murine MOG-induced multiple sclerosis model. Neurobiology of Disease, 54, 382-391. https://doi.org/10.1016/j.nbd.2013.01.012

  • Choi, S., et al. (2018). Zinc in the Brain: Friend or Foe? International Journal of Molecular Sciences, 19(12), 3961. https://doi.org/10.3390/ijms19123961

  • Hopkins, L. L., et al. (1987). Multiple sclerosis and the workplace: report of an industry-based cluster study. Archives of Environmental Health, 42(2), 85-89. https://doi.org/10.1080/00039896.1987.9935803

  • Kahraman, A., et al. (2017). Modulation of Multiple Sclerosis and Its Animal Model Experimental Autoimmune Encephalomyelitis by Food and Gut Microbiota. Frontiers in Immunology, 8, 1081. https://doi.org/10.3389/fimmu.2017.01081

  • Landtblom, A. M., et al. (1996). Organic solvents and multiple sclerosis: a synthesis of the current evidence. Epidemiology, 7(4), 429-433. https://doi.org/10.1097/00001648-199607000-00016

  • Mirza, A., et al. (2022). The Gut Microbiome in Multiple Sclerosis: A Potential Therapeutic Avenue. Medical Sciences, 10(4), 69. https://doi.org/10.3390/medsci10040069

  • Miyamoto, K., et al. (2010). The interaction of zinc with membrane-associated 18.5 kDa myelin basic protein: an attenuated total reflectance-Fourier transform infrared study. Amino Acids, 39(5), 1481-1489. https://doi.org/10.1007/s00726-010-0599-7

  • Pawlitzki, M., et al. (2018). Lower Serum Zinc Levels in Patients with Multiple Sclerosis Compared to Healthy Controls. Nutrients, 10(8), 1141. https://doi.org/10.3390/nu10081141

  • Pederick, V. G., et al. (2015). ZnuA and zinc homeostasis in Pseudomonas aeruginosa. Scientific Reports, 5, 13139. https://doi.org/10.1038/srep13139

  • Praet, J., et al. (2014). Cellular and molecular neuropathology of the cuprizone mouse model: clinical relevance for multiple sclerosis. Neuroscience & Biobehavioral Reviews, 47, 485-505. https://doi.org/10.1016/j.neubiorev.2014.10.004

  • Ristori, G., et al. (2023). Elevated Fecal Calprotectin Accompanied by Intestinal Neutrophil Infiltration in Experimental Autoimmune Encephalomyelitis. Cellular and Molecular Gastroenterology and Hepatology, 16(5), 785-804. https://doi.org/10.1016/j.jcmgh.2023.07.003

  • Eliaeson, Karin & Liljeberg, Marcus & Björk, Anders & Kockum, Ingrid & Lindström, Eva & Skelton, Alasdair. (2009). Relationships of geochemistry and multiple sclerosis.

  • Boddy, S. L., et al. (2021). The gut microbiome: a key player in the complexity of amyotrophic lateral sclerosis (ALS). BMC Medicine, 19(1), 13. https://doi.org/10.1186/s12916-020-01885-3

Disclaimer: This post is for informational purposes only and does not constitute medical advice. All claims are supported by cited research, but interpretations are my own.